TCGA-21-1076-01A-01R-0692-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 54
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.510
- INFLAMMATORY_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- KRAS_SIGNALING_UP+0.410
- COMPLEMENT+0.400
- COAGULATION+0.380
- HEDGEHOG_SIGNALING+0.380
Top 10 suppressed
- MYC_TARGETS_V2-0.490
- OXIDATIVE_PHOSPHORYLATION-0.350
- DNA_REPAIR-0.320
- MYC_TARGETS_V1-0.280
- E2F_TARGETS-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.220
- PEROXISOME-0.210
- GLYCOLYSIS-0.200
- ADIPOGENESIS-0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-1076-01A-02R-0692-07 | — | cohortSQ1 | 0.952 |
| 2 | DRR168577 | — | — | 0.906 |
| 3 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.895 |
| 4 | SRR12202441 | — | — | 0.889 |
| 5 | BS_02NZT8CE | low-grade glioma | — | 0.888 |
| 6 | SRR8613803 | — | D | 0.886 |
| 7 | MDT-AP-2869 | Med | Medulloblastoma | 0.886 |
| 8 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.880 |
| 9 | BS_JBGZ7HHZ | ganglioneuroblastoma | — | 0.879 |
| 10 | SRR8613789 | — | A | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |